
The baby formula shortage that has morphed into a crisis in the U.S. could soon see some relief following an agreement between market leader Abbott Laboratories (NYSE:ABT) and the Food and Drug Administration.
What Happened: Abbott announced late Monday that it has agreed to enter into a consent decree with the FDA regarding the restart of production at the former's Sturgis, Michigan infant formula plant.